UnknownPhase 2

Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

Egypt70 participantsStarted 2023-12-15

Plain-language summary

Breast cancer, a leading cause of cancer-related mortality in women worldwide, has spurred the investigation of novel therapeutic approaches. Pentoxifylline (PTX), a synthetic methylxanthine derivative, has shown promise in preclinical studies when combined with conventional anticancer drugs. This study aims to assess PTX's impact when added to neoadjuvant chemotherapy protocols in breast cancer patients, with the goal of improving treatment outcomes and reducing associated toxicities.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult female patients \>18 years old with histologic confirmation of invasive breast cancer * Planned to administer neoadjuvant chemotherapy protocol comprised of doxorubicin/ cyclophosphamide followed by paclitaxel (AC/T) * Adequate hepatic, renal, and bone marrow functions Exclusion Criteria: * Patients on treatment regimen of phosphodiesterase inhibitors * Patients who are taking antiplatelet or anticoagulant treatment * Patients who are allergic to phosphodiesterase inhibitors * History of recent hemorrhagic events * Active peptic ulcer

What they're measuring

Relative reduction in tumor size after neoadjuvant chemotherapy treatment

Timeframe: 6 months

Trial details

NCT IDNCT06176339

SponsorMansoura University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-30

View on ClinicalTrials.gov More Breast Cancer Female trials